Table 5 Univariate and multivariate analyses for OS of ovarian cancer
Variable | n (%) | Median (months) | p value |
|---|---|---|---|
Age: | |||
<70 | 118 (94.4 %) | 46.0 | 0.022 |
≥70 | 7 (5.6 %) | 14.8 | |
Performance status WHO: | |||
▪ 0 | 19 (15.2 %) | NR | 0.28 |
▪ Other | 106 (84.8) | 36.2 | |
FIGO stage: | |||
▪ Early (I,II) | 24 (19.2 %) | NR | 0.003 |
▪ Advanced (III, IV) | 101 (80.8 %) | 33.3 | |
Chemotherapy regimen: | |||
▪ With paclitaxel | 113 (90.4 %) | 46.1 | 0.035 |
▪ Without paclitaxel | 12 (9.6 %) | 16.6 | |
Chemotherapy regimen: | |||
▪ With cisplatin | 55 (44.0 %) | 50.5 | 0.24 |
▪ With carboplatin | 70 (56.0 %) | 32.3 | |
Type of histology: | |||
▪ Serous | 68 (54.4 %) | 33.2 | 0.047 |
▪ Other | 57 (45.6 %) | NR | |
Grading: | |||
▪ 1 and 2 | 45 (36.0 %) | 49.8 | 0.53 |
▪ 3 and unspecified | 80 (64.0 %) | 35.6 | |
Primary surgery: | |||
▪ Optimal (<1 cm) | 77 (61.6 %) | 51.8 | 0.028 |
▪ Suboptimal (>1 cm) | 48 (38.4 %) | 30.0 | |
BRCA1 status: | |||
▪ Wild type | 108 (86.4 %) | 35.6 | 0.041 |
▪ Germline mutation | 17 (13.6 %) | NR | |
Multivariate analysis | |||
Variable | HR (95 % CI) | p value | |
Age: | |||
<70 | 0.15 (0.053 – 0.417) | < 0.001 | |
≥70 | |||
Primary surgery: | |||
▪ Optimal (<1 cm) | 0.39 (0.205 – 0.715) | 0.003 | |
▪ Suboptimal (>1 cm) | |||
BRCA1 status: | |||
▪ Germline mutation | 0.14 (0.032 – 0.650) | 0.012 | |
▪ Wild type | |||